140234 - Individualising care – considerations in the escalation of pharmacological management of type 2 diabetes
- : Online
GPs continue to leave type 2 diabetes patients on metformin monotherapy for too long when they are no longer achieving target HbA1c levels.
Even when aware of options, when it comes to adding a second agent they tend to prescribe their favourite therapy with little regard to individual patient requirement.
This is compounded by the fact there are a number of newer DPP-4 agents, SGLT-2 agents and even GLP-1 agents all competing as first line therapy after metformin.
This educational module stresses the importance of reaching HbA1c targets and early on using the most appropriate agent to add on to metformin
A sustained legacy effect of intensive glucose-management in type 2 diabetes has been observed, indicating a continued reduction in microvascular risk. In addition, the legacy effect demonstrates an association between intensive glucose management and a significantly decreased risk of myocardial infarction and death.
Over 60% of patients are reported as not achieving their glycaemic goals. One Australian study showed less than half of patients with type 2 diabetes seen in general practice had an HbA1c = 7% (53 mmol/mol) with 25% having an HbA1c > 8% (64mmol/mol).